QUARTERLY STATEMENT

OF THE

Athene Annuity and Life Company

TO THE

Insurance Department

OF THE

STATE OF

FOR THE QUARTER ENDED MARCH 31, 2021

[] LIFE, ACCIDENT AND HEALTH

[] FRATERNAL BENEFIT SOCIETIES

2021

ASSETS

			Current Statement Date		4
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	December 31 Prior Year Net Admitted Assets
1.	Bonds	42,287,499,097		42,287,499,097	39,805,410,008
	Stocks:				
	2.1 Preferred stocks	316,524,252		316,524,252	218,269,833
	2.2 Common stocks	572,272,109		572,272,109	586,370,677
3.	Mortgage loans on real estate:				
	3.1 First liens	8,482,028,922		8,482,028,922	7,521,955,314
	3.2 Other than first liens	1,284,102,109		1,284,102,109	1,265,440,502
4.	Real estate:				
	4.1 Properties occupied by the company (less \$ encumbrances)				
	4.2 Properties held for the production of income (less				
	\$encumbrances)	9,388,542		9,388,542	9,388,542
	4.3 Properties held for sale (less \$ encumbrances)				
5.	Cash (\$461,470,503), cash equivalents				
0.	(\$) and short-term				
	investments (\$	3 065 192 930		3,065,192,930	3 807 048 181
6.	Contract loans (including \$ premium notes)			142,025,148	147,255,534
7.	Derivatives Premium notes)				792,640,026
8.	Other invested assets				2,626,686,740
9.	Receivables for securities		1, 101,201	101,492,467	70,904,845
10.	Securities lending reinvested collateral assets			101, 102, 101	70,001,010
11.	Aggregate write-ins for invested assets			52,763,118	
12.	Subtotals, cash and invested assets (Lines 1 to 11)			60,948,618,019	
	Title plants less \$ charged off (for Title insurers		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	only)				
14.	Investment income due and accrued			478,011,098	462.340.191
	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection				5,497
	15.2 Deferred premiums, agents' balances and installments booked but				,
	deferred and not yet due (including \$				
	earned but unbilled premiums)	6,896,748		6,896,748	6,741,197
	15.3 Accrued retrospective premiums (\$, ,		, ,	, ,
	contracts subject to redetermination (\$				
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	231,677,223		231,677,223	230,176,940
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts			1, 163, 696, 835	1,564,892,451
17.	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon			14,836,884	7,443,646
	Net deferred tax asset				11,861,594
19.	Guaranty funds receivable or on deposit			639,640	639,640
20.	Electronic data processing equipment and software				
21.	Furniture and equipment, including health care delivery assets (\$				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates			556,365	
24.	Health care (\$) and other amounts receivable			55,600,602	, ,
25.	Aggregate write-ins for other than invested assets			414,580,105	
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			63,323,077,728	59,680,279,192
27.	From Separate Accounts, Segregated Accounts and Protected Cell	10 000 711 505		19,922,714,505	16,875,242,438
20	Accounts Total (I inco 26 and 27)	83,279,280,089	22 407 055	83,245,792,233	76,555,521,630
28.	Total (Lines 26 and 27)	03,219,200,009	33,487,855	03,243,792,233	70,555,521,650
4404	Derivative Collateral Asset	EQ 760 110		EQ 760 110	70 100 115
1102.				52,763,118	/3, 193, 113
1103.	Output of a state of the state				
1198.	Summary of remaining write-ins for Line 11 from overflow page			F2 762 110	70 400 445
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	52,763,118		52,763,118	73, 193, 115
2501.	Corporate Owned Life Insurance (COLI)			413,305,148	411,640,578
2502.	Miscellaneous Assets			1,274,957	873,950
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				440 544 500
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	426,915,484	12,335,379	414,580,105	412,514,528

LIABILITIES, SURPLUS AND OTHER FUNDS

	·	1	2
		Current	December 31
		Statement Date	Prior Year
1.	Aggregate reserve for life contracts \$46, 162, 139, 336 less \$ included in Line 6.3		
	(including \$36,940,189,891 Modco Reserve)	46, 162, 139, 336	46,015,816,240
	Aggregate reserve for accident and health contracts (including \$		
3.	Liability for deposit-type contracts (including \$5,091,039,158 Modco Reserve)	5, 157, 569, 600	2, 107, 173, 943
4.	Contract claims:		
	4.1 Life		228,035,868
	4.2 Accident and health	11,883	12,583
5.	Policyholders' dividends/refunds to members \$ and coupons \$ due		
	and unpaid		
6.	Provision for policyholders' dividends, refunds to members and coupons payable in following calendar year - estimated		
	amounts:		
	6.1 Policyholders' dividends and refunds to members apportioned for payment (including \$		
	Modco)		
	6.2 Policyholders' dividends and refunds to members not yet apportioned (including \$ Modco)		
	6.3 Coupons and similar benefits (including \$		
7.	Amount provisionally held for deferred dividend policies not included in Line 6		
8.	Premiums and annuity considerations for life and accident and health contracts received in advance less		
	\$ discount; including \$ accident and health premiums		4 , 180
9.	Contract liabilities not included elsewhere:		
	9.1 Surrender values on canceled contracts		
	9.2 Provision for experience rating refunds, including the liability of \$ accident and health		
	experience rating refunds of which \$ is for medical loss ratio rebate per the Public Health		
	Service Act		
	9.3 Other amounts payable on reinsurance, including \$ assumed and \$2,613,668,814		
	ceded	2.613.668 814	2.611.669.078
	9.4 Interest Maintenance Reserve		
10	Commissions to agents due or accrued-life and annuity contracts \$ 9,780,267 , accident and health	, ,	, ,
10.	\$ and deposit-type contract funds \$	9 780 267	8 408 370
11			
11.	Commissions and expense allowances payable on reinsurance assumed		
12.	General expenses due or accrued	22,877,054	22, 101,992
13.	Transfers to Separate Accounts due or accrued (net) (including \$	4 000 577 401	0 000 101 105
	allowances recognized in reserves, net of reinsured allowances)	1,996,5//,461	2,026,424,135
14.	Taxes, licenses and fees due or accrued, excluding federal income taxes		662,400
	Current federal and foreign income taxes, including \$ on realized capital gains (losses)		
15.2	Net deferred tax liability		
16.	Unearned investment income		
	Amounts withheld or retained by reporting entity as agent or trustee		
18.	Amounts held for agents' account, including \$1,459,196 agents' credit balances	1,459,196	2,211,997
19.	Remittances and items not allocated	117, 148, 914	153,461,203
20.	Net adjustment in assets and liabilities due to foreign exchange rates		
21.	Liability for benefits for employees and agents if not included above	27,067	104 , 155
22.	Borrowed money \$ and interest thereon \$		
23.	Dividends to stockholders declared and unpaid		
I	Miscellaneous liabilities:		
	24.01 Asset valuation reserve	1 073 973 009	940 517 699
	24.02 Reinsurance in unauthorized and certified (\$		
	24.03 Funds held under reinsurance treaties with unauthorized and certified (\$	1 313 414 135	1 323 388 253
	24.04 Payable to parent, subsidiaries and affiliates		
	24.05 Drafts outstanding		
	24.06 Liability for amounts held under uninsured plans 24.07 Funds held under coinsurance		
	24.08 Derivatives	151 064 446	151 442 626
	24.09 Payable for securities		
	24.10 Payable for securities lending		
0.5	24.11 Capital notes \$ and interest thereon \$		2 200 222 500
l l	Aggregate write-ins for liabilities	3,467,776,249	3,388,232,588
26.	Total liabilities excluding Separate Accounts business (Lines 1 to 25)	62,907,795,851	59,162,365,612
27.	From Separate Accounts Statement		16,080,921,495
28.	Total liabilities (Lines 26 and 27)	82,034,145,295	75,243,287,107
29.	Common capital stock	, ,	, ,
30.	Preferred capital stock		
31.	Aggregate write-ins for other than special surplus funds		
32.	Surplus notes		
33.	Gross paid in and contributed surplus	1, 176, 574, 698	1, 173, 382, 497
34.	Aggregate write-ins for special surplus funds		
35.	Unassigned funds (surplus)		
36.	Less treasury stock, at cost:		
	36.1shares common (value included in Line 29 \$		
	36.2 shares preferred (value included in Line 30 \$		
37.	Surplus (Total Lines 31+32+33+34+35-36) (including \$	1,201,646,939	1,302,234,523
38.	Totals of Lines 29, 30 and 37	1,211,646,939	1,312,234,523
39.	Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3)	83,245,792,233	76,555,521,630
	DETAILS OF WRITE-INS	, -,,	,,,
2501.	Derivative and Other Collateral Liability	2.619.700 750	2,568,159,698
2502.	Repurchase Agreement Liability		598,358,554
2503.	Miscellaneous Liability		79,009,651
2598.	Summary of remaining write-ins for Line 25 from overflow page		142,704,685
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	3,467,776,249	3,388,232,588
3101.	Totals (Lines 250 Fillhough 2505 plus 2596)(Line 25 above)		3,300,232,300
3102.			
3103.	Output of annual in the line feeling Officer and output		
3198.	Summary of remaining write-ins for Line 31 from overflow page		
3199.	Totals (Lines 3101 through 3103 plus 3198)(Line 31 above)		
3401.			
3402.			
3403.			
3498.	Summary of remaining write-ins for Line 34 from overflow page		
3499.	Totals (Lines 3401 through 3403 plus 3498)(Line 34 above)		
		·	

SUMMARY OF OPERATIONS

Performance and analysis persolemistre for tile and scored and health centralized:			1 1	2	3
Projection and anothic considerables for the and accord and Poeth contracts 75 (7% 30) 80 (3) 157 (1) 81 (3) 1			•		
1. Premium and annual considerations for life and accorded and health contracts.					
2 Contractements for supprensitive contracts with this continguancies.	1.	Premiums and annuity considerations for life and accident and health contracts			
3. No investment incomes Amontained incomes or Release Nation Amontained in three Delinosemon Release Nation Amontained in three Delinosemon Release Nation Amontained incomes Amontained Nation					, , ,
4. A protocation of lowered television received granularizing granularizing and received (%) 2, 24, 44, 46, 16, 16, 10, 10, 10, 11, 11, 12, 12, 12, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14					, ,
5 Source Accounts and garden alternative considering sensitivity growth on generative considering sensitivities of sensitivities and expense alternative considering sensitivities (193 Med 527 (193				, ,	
6. Commissions and expenses activarances content among and content of 179,000,000,000,000,000,000,000,000,000,0					, , ,
7.6 1966, 2022 1953, 302, 388 1, 1, 494, 325, 481		Commissions and expense allowances on reinsurance ceded	209.898.877	, , ,	
8. Miscolaronics income 8.1 Income from these searcialed with investment management, administration and contact 8.2 Charges and fiest for disposal type controls. 8.2 Charges and fiest for disposal type controls. 8.3 Aggregate with less for miscolaron income. 8.4 (48 ft 15		Reserve adjustments on reinsurance ceded	(751.946.622)		
B. Income from Ness associated with investment immagnement, administration and contract Operating the time Septiate Account instants Contract Cont					
guarantees from Separate Accounts 8.7 This page of contracts 8.7 This page of the separate Accounts 8.7 This page of the separate Accounts of the separate Accounts of Page 11 this page of the separate Accounts of Page 12 this page 12 th					
8.2 Charges and fees for depend upon contracts. 8.3 A Charges with white 9 to Principation (Income 1, 15, 16, 17, 17, 18, 17, 19, 19, 10) 9.3 Sold provides 1, 17, 17, 17, 18, 17, 19, 19, 10, 10, 17, 12, 19, 19, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11		guarantees from Separate Accounts	2,767,103	1,811,492	7,756,121
8.5 Agragates with a 50 x 30 x 10 x 30 x 3				, . , , , ,	,
1.123.167.78		•		(4 590 752)	28 269 570
10	a	99 9			
1.1 Matured endocuments (excluding guaranteed armust pure endocuments)		· · · · · · · · · · · · · · · · · · ·		,.,	
12					
13. Disability bornelfs and bornels under accident and health contracts. 94.277 97.855 384, 145 15. Summerine breeffls and disablesish for life contracts. 15. 1		Matured endowments (excluding guaranteed annual pure endowments)	100 100 211	00,005,000	
14. Coupons, guaranteed amuse pure ondowness and services		Annuity benefits	120, 190,311		
15. Sumedard benefits and shirtidinavish for life controllates 10.015,084 18.15,791 70.02.45,891	-				
16. Group commerciation 153 264, 839 3, 456, 637 155, 834, 440 174, 174, 174, 174, 174, 174, 174, 174,					
17. Interest and aglishments on contract or depose-type contract funds 1,3,254,659 3,346,057 5,5,544,401 19. Peyments on supplementary contracts with life contracts 1,3,77,076 19.	_			188, 135, 791	, ,
18. Psyments on supprenentary contracts with the contingencies 3,379,984 5,381,225 10,477,769 17,809,207 173,003,207	16.				
19. Increase in aggregate reserves for tile and accident and health contracts 146, 312, 737 20, 20, 20, 98 147, 708, 1965 187, 708, 1967 180, 708, 197 180, 709,	17.	Interest and adjustments on contract or deposit-type contract funds	(133,254,839)	3,436,037	(55,934,440)
200 Totals (Lines 10 to 19) 201 Commission on premiums, annuity considerations, and deposit-type contract funds (direct 13:88, 48) 18, 193 103, 80 18, 193 103, 80 18, 193 18, 193 193		Payments on supplementary contracts with life contingencies	3,579,994	5,319,125	10,477,476
200 Totals (Lines 10 to 19) 201 Commission on premiums, annuity considerations, and deposit-type contract funds (direct 13:88, 48) 18, 193 103, 80 18, 193 103, 80 18, 193 18, 193 193	19.				871 <u>,</u> 352,764
22. Commissions on premiums, annually conditionations, and deposit byte contract funds (direct byte-incress only) pursue allowance on reinaurance assumed 133,304,318 103,870,078 522,27;181				144,768,064	1,897,954,347
Display		Commissions on premiums, annuity considerations, and deposit-type contract funds (direct	, ,	, ,	, , ,
22 Commissions and opportune allowances on reinsurance assumed 133,340 188,55 158,527,255 24 Insurance taxes, scorese and fees, excluding federal income taxes 157,43,91 186,55 158,527,255 25 Insurance taxes, scorese and fees, excluding federal income taxes 15,948,365 15,948,365 26 Insurance taxes, scorese and fees, excluding federal income taxes 16,947,205 15,948,265 27 Agricagite write-ins for deductions 16,948,265 11,134,945 15,948,365 28 Notes and the second of t		business only)	135,304,318		526,257,181
22. General insurance expenses and features depended and processes .968, 794, 901 .81, 835, 621 .855, 655 .856, 556 .856	22.	Commissions and expense allowances on reinsurance assumed	133,940	198,810	1,086,162
24	23.	General insurance expenses and fraternal expenses	106,734,901	81,835,061	
25 Norease in loading on deferred and uncollected premiums 1 1 1 1 1 1 1 1 1		Insurance taxes, licenses and fees, excluding federal income taxes	6,452.205		
22. Net transfers to or (from) Separate Accounts net of reinsurance			, , ,	1	
27 Aggregate will-sins for deductions			546 914 439	170 126 025	
28. Trains (Lines 20 to 27)					
22. Net gain from operations before dividends to policyholders and federal income taxes (Line 9 minus Line 28) 10,686,260 19,217,377 72,649,417 (202) (202			. , , , ,		
Line 28) 19, 217, 377 7, 72, 684, 417 (2022)		· ·	1,110,040,400	310,013,302	3,003,303,710
30 Dividends to policyholders and refunds to members (382) (282)	29.	Net gain from operations before dividends to policyholders and federal income taxes (Line 9 minus	10 600 260	10 217 277	72 640 417
31 Net gain from operations after dividends to policyholders, refunds to members and before federal income taxes (Line 29 minus Line 39) 10, 689, 280 19, 277, 689 72, 649, 709 32. Federal and foreign income taxes incurred (excluding tax on capital gains) 10, 088, 710 80, 309, 716 44, 155, 735 38. Net gain from operations after dividends to policyholders, refunds to members and federal income taxes and before realized capital gains (of losses) (Line 31 minus Line 32) 29, 734, 970 (61, 292, 047) 28, 482, 954 39, 39, 39, 39, 39, 39, 39, 39, 39, 39,	00		10,090,200	, ,	, ,
income taxes (Line 20 minus Line 30)		' '		(292)	(292)
32. Pederal and foreign income taxes incurred (excluding tax on capital gains) 10,086,710 80,509,716 44,166,755 13. Net gain from operations after dividends to prolicyholders, refunds to members and festeral income taxes and before realized capital gains and colorises) (Line 31 minus Line 32) 20,734,970 (61,292,047) 22,892,954 23,892,954 24,892,95	31.	Net gain from operations after dividends to policyholders, refunds to members and before federal	10 600 060	10 217 660	70 640 700
33. Net gain from operations after dividends to policyholdises, refunds to members and federal income taxes and before realized capital gains (isoses) (excluding gains (isoses) (in 34 minus Line 32). 20,734,970 (61,22,047) 28,492,954 34. Net realized capital gains (isoses) (excluding gains (isoses) (in 34 minus Line 32). (15,680 minus Line 34) (16,680 min	00				, ,
taxiss and before realized capital gains or (iosses) (Lind 31 minus Line 32). 4. Not realized capital gains (iosses) (excluding taxes of \$ 8,705,889 4. Taxisfered to the IMR) (iosses) (excluding taxes of \$ 8,705,889 5. Not Income (Line 33 plus Line 34). Capital and surplus, December 31, prior year. 5. Capital and surplus, December 31, prior year. 6. Capital and surplus, December 31, prior year. 7. Not Income (Line 35). 7. Not Income (Line 35). 8. Change in net unealized capital gains (losse) less capital gains tax of \$ 25,103,224 1.22, 245,233 1.208, 647,744 1.208, 647,744 1.208, 647,74		• • • • • • • • • • • • • • • • • • • •	(10,036,710)	80,309,716	44, 100, 700
34. Net realized capital gains (losses) (excluding gains (losses) transferred to the IMIR) less capital gains tax of \$ (1.566,206) (excluding taxes of \$ 8,705,868 11,830,539 (15,056,565) (38,456,667) (39,456,	33.		20 724 070	(61 000 047)	00 400 054
gains tax of \$			20,734,970	(61,292,047)	28,492,954
Vanishered to the MR 11,830,339 (15,050,565) (36,456,667) (7,953,713) (7,	34.				
35. Net income (Line 33 plus Line 34). 22,585,509 (76,342,611) (7,983,713)				/ /= a=a =a=x	(00 450 005)
Capital and surplus, December 31, prior year 1,312,234,523 1,208,647,744 1,208,647,744 37. Net income (Line 35) 32,365,509 (76,342,611) (77,363,713) 38. Change in net unrealized capital gains (losses) less capital gains tax of \$ 25,103,224 142,707,026 (59,141,458) (37,881,637) 39. Change in net unrealized foreign exchange capital gain (loss) (2,837,721 15,076,309 43,241,719 40. Change in net unrealized foreign exchange capital gain (loss) (2,837,721 15,076,309 43,241,719 40. Change in notadmitted assets (8,233,611) (2,919,995 70,888,258 83,641,668 41. Change in notadmitted assets (8,223,611) (2,919,995 70,888,258 83,641,668 74. Change in liability for reinsurance in unauthorizzed and certified companies (8,233,611) (8,233,611) (8,233,611) (1,543,616,611) (1,			, . ,		
36	35.	Net income (Line 33 plus Line 34)	32,565,509	(76,342,611)	(7,963,713)
37. Net income (Line 35) 32 565 509 176 342 6111 17 ,983 7313		CAPITAL AND SURPLUS ACCOUNT			
37. Net Income (Line 35) 32,565,599 776,342,6111 77,963,773 38. Change in net unrealized capital gains (losses) less capital gains tax of \$ 25,103,224 132,670,026 (58, 141,459) (37, 881,857) 39. Change in net unrealized foreign exchange capital gain (loss) 1,206,839 70,881,857 15,076,309 43,241,719 10,000	36.	Capital and surplus, December 31, prior year	1,312,234,523	1,208,647,744	1,208,647,744
38. Change in net unnealized capital gains (losses) less capital gains tax of \$ 25, 103, 224 39. Change in net unnealized foreign exchange capital gain (loss) 40. Change in net undealized foreign exchange capital gain (loss) 41. Change in net deferred income tax 42. Change in net deferred income tax 43. Change in net deferred income tax 44. Change in lability for reinsurance in unauthorized and certified companies 45. Change in reserve on account of change in valuation basis, (increase) or decrease 46. Change in asset valuation reserve 47. Change in saset valuation reserve 48. Change in saset valuation reserve 49. Change in treasury stock 40. Surplus (contributed to) withdrawn from Separate Accounts during period 41. Change in surplus in Separate Accounts Statement 42. Change in surplus in Separate Accounts Statement 43. Surplus (contributed to) withdrawn from Separate Accounts Uning period 44. Change in surplus in Separate Accounts Statement 45. Surplus contributed by withdrawn from Separate Accounts Statement 46. Change in surplus in Separate Accounts Statement 47. Change in surplus in Separate Accounts Statement 48. Change in surplus in Separate Accounts Statement 49. Cumulative effect of changes in accounting principles 50. Capital changes: 50. 1 Paid in 50. 2 Transferred from surplus (Stock Dividend) 51.3 Transferred from surplus (Stock Dividend) 51.3 Transferred to capital (Stock Dividend) 51.3 Transferred to capital (Stock Dividend) 51.3 Transferred to capital (Stock Dividend) 51.3 Transferred from surplus as a result of reinsurance 51.4 Change in surplus and surplus for the year (Lines 37 through 53) 51.4 Change in surplus and surplus for the year (Lines 37 through 53) 51.4 Change in surplus and surplus for the year (Lines 37 through 53) 51.4 Change in surplus and surplus for the year (Lines 37 through 53) 51.4 Change in surplus and surplus for the year (Lines 37 through 53) 51.4 Change in surplus and surplus for the year (Lines 37 through 53) 51.4 Change in surplus and surplus for the year (Lines 37 th	37.			(76.342.611)	(7.963.713)
3.9 Change in net unrealized foreign exchange capital gain (loss)					
40. Change in net deferred income tax					, , , ,
41. Change in nonadmitted assets (8, 23, 561) 2, 919, 995 (15, 403, 773) 42. Change in reinsurance in unauthorized and certified companies 43. Change in reserve on account of change in valuation basis, (increase) or decrease 44. Change in reserve valuation reserve (133, 455, 310) (142, 819, 260) 45. Change in treasury stock (465, 000, 000) 46. Surplus (contributed to) withdrawn from Separate Accounts during period (465, 000, 000) 47. Other changes in surplus in Separate Accounts Statement (13, 985, 994) 701, 355 345, 999, 752 48. Change in surplus notes (13, 985, 994) 701, 355 345, 999, 752 49. Cumulative effect of changes in accounting principles (13, 985, 994) 701, 355 345, 999, 752 50. Paid in (13, 985, 994) 701, 355 345, 999, 752 50. Tansferred to surplus (Stock Dividend) (13, 985, 994) 701, 355 345, 999, 752 50. Transferred to surplus (Stock Dividend) (13, 985, 994) 701, 355 345, 999, 752 51. Paid in (14, 986, 999, 752 799, 799, 799, 799, 799, 799, 799, 79		Change in net deferred income tax	21 205 839	70 888 258	
42. Change in lability for reinsurance in unauthorized and certified companies 43. Change in reserve on account of change in valuation basis, (increase) or decrease 44. Change in asset valuation reserve 45. Change in sesure valuation reserve 46. Surplus (contributed to) withdrawn from Separate Accounts during period 47. Other changes in surplus in Separate Accounts during period 48. Change in surplus part of the separate Accounts Statement 49. Change in surplus part of the separate Accounts Statement 49. Change in surplus part of the separate Accounts Statement 49. Cumulative effect of changes in accounting principles 50. Capital changes: 50.1 Paid in 50.2 Transferred from surplus (Stock Dividend) 50.3 Transferred from surplus (Stock Dividend) 51.2 Transferred to capital (Stock Dividend) 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance 52. Dividends to stockholders 53. Aggregate write-ins for gains and losses in surplus 54. Net change in capital and surplus as a fisal part of the year (Lines 37 through 53) 55. Capital and surplus, as of statement date (Lines 36 + 54) 56. Capital and surplus, as of statement date (Lines 36 + 54) 57. DETAILS OF WRITE-INS 58. DETAILS OF WRITE-INS 59. OBJECT (Statement County Page) 59. Transferred to Line Statement date (Lines 36 + 54) 59. Transferred to Line Statement date (Lines 36 + 54) 59. Transferred to Line Statement date (Lines 36 + 54) 59. Transferred to Line County Page 59. Transfer to IMP - Ceded 59. Summary of remaining write-ins for Line 27 from overflow page 59. Transfer to IMP - Ceded 59. Summary of remaining write-ins for Line 27 from overflow page 59. Transfer to IMP - Ceded 59. Summary of remaining write-ins for Line 27 from overflow page 59. Transfer to IMP - Ceded 59. Summary of remaining write-ins for Line 27 from overflow page 59. Summary of remaining write-ins for Line 27 from overflow page 59. Summary of remaining write-ins for Line 58 from		Change in nonadmitted assets	(8 223 561)	2 010 005	
43. Change in reserve on account of change in valuation basis, (increase) or decrease (133,455,310) (61,953,812 (142,819,260) (45. Change in treasury stock (45. Change in treasury stock (465,000,000) (465,0					
44. Change in asset valuation reserve		·			
46. Surplus (contributed to) withdrawn from Separate Accounts during period 47. Other changes in surplus in Separate Accounts Statement. 48. Surplus (contributed to) withdrawn from Separate Accounts Statement. 49. Cumulative effect of changes in accounting principles 50. Capital changes: 50.1 Paid in 50.2 Transferred from surplus (Stock Dividend) 50.3 Transferred to surplus 51. Surplus adjustment 51.1 Paid in 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance 51.4 Change in surplus as a result of reinsurance 52. Dividends to stockholders 53. Aggregate write-ins for gains and losses in surplus 54. Net change in capital and surplus for the year (Lines 37 through 53) 55. Capital and surplus, as of statement date (Lines 36 + 54) 56. Capital and surplus, as of statement date (Lines 36 + 54) 57. Capital surplus (10,054,054) 58. OF WRITE-INS 59. DETAILS OF WRITE-INS 59. OF WRITE-INS 5					
46, 20,					
47. Other changes in surplus in Separate Accounts Statement (13,985,094) 701,355 445,969,752 48. Change in surplus notes 49. Cumulative effect of changes in accounting principles 50. Capital changes: 50.1 Paid in 50.2 Transferred from surplus (Stock Dividend) 50.3 Transferred to surplus 51. Surplus adjustment: 51.1 Paid in 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance 51.4 Change in surplus as a result of reinsurance 51.5 Puvidends to stockholders 52. Dividends to stockholders 53. Aggregate write-ins for gains and losses in surplus 54. Net change in capital and surplus for the year (Lines 37 through 53) 55. Capital and surplus, as of statement date (Lines 36 + 54) 56. Capital and surplus, as of statement date (Lines 36 + 54) 57. Capital and surplus see (1,4,378,395) 58. DETAILS OF WRITE-INS 59. OB WR					
48. Change in surplus notes Camulative effect of changes in accounting principles Capital changes: 50. Paid in 50. 2 Transferred from surplus (Stock Dividend) 50.3 Transferred to surplus 51. Paid in 50.2 Transferred to surplus 51. Paid in 51. Transferred to capital (Stock Dividend) 51.3 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance (137, 387, 518) 100, 935, 259 (11, 054, 682) Dividends to stockholders 52. Dividends to stockholders 53. Aggregate write ins for gains and losses in surplus (4, 375, 905) 179, 457 (775, 304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100, 587, 584) 121, 579, 320 103, 586, 779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1, 211, 646, 633 1, 330, 227, 064 1, 312, 234, 523 DETAILS OF WRITE-INS 08, 301. COL I Income 4, 798, 747 4, 486, 607) 28, 655, 662 08, 302. Miscel laneous Expense (102, 633) (104, 145) (386, 092) 08, 399. Totals (Lines 08, 301 through 08, 303 plus 08, 398) (Line 8, 3 above) 4, 696, 115 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 115 4, 690, 752 4, 696, 690 4, 696, 115 4, 690, 752 4, 696, 690 4, 696, 115 4, 690, 752 4, 690,		Surplus (contributed to) withdrawn from Separate Accounts during period			(465,000,000)
49. Cumulative effect of changes in accounting principles 50. Capital changes: 50.1 Paid in 50.2 Transferred from surplus (Stock Dividend) 50.3 Transferred to surplus 51.1 Paid in 51.1 Paid in 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance 51.4 Change in surplus as a result of reinsurance 51.5 Dividends to stockholders 51.5 Aggregate write-ins for gains and losses in surplus 51.4 Change in capital and surplus for the year (Lines 37 through 53) 51.5 Aggregate write-ins for gains and losses in surplus 51.5 Capital and surplus, as of statement date (Lines 36 + 54) 51.5 Capital and surplus, as of statement date (Lines 36 + 54) 51.5 Capital and surplus, as of statement date (Lines 36 + 54) 51.5 Capital and surplus and surplus for the year (Lines 37 through 53) 51.5 Capital and surplus and surplus for the year (Lines 37 through 53) 51.7 Capital and surplus as of statement date (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 37 through 53) 51.7 Capital and surplus as of statement date (Lines 36 + 54) 51.7 Capital and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 36 + 54) 51.7 Capital and surplus and surplus for the year (Lines 37 through 27 64	47.				
50. Capital changes:	48.				
50.1 Paid in 50.2 Transferred from surplus (Stock Dividend) 50.3 Transferred to surplus (Stock Dividend) 50.3 Transferred to surplus (Stock Dividend) 51.5 Surplus adjustment: 3,192,201 3,408,944 211,432,030 512 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance (137,387,518) 100,935,259 (111,054,682) 52. Dividends to stockholders (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS (100,1887,584) 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS (100,1887,584) 1,330,227,064 1,3312,234,523 (100,1887,1887,189,1897,1897,1897,1897,1897,	49.	Cumulative effect of changes in accounting principles			
50.2 Transferred from surplus (Stock Dividend) 50.3 Transferred to surplus 51. Surplus adjustment: 51.1 Paid in	50.				
50.3 Transferred to surplus 51. Surplus adjustment: 51.1 Paid in 3,192,201 3,408,944 211,432,030 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance (137,387,518) 100,935,259 (111,054,682) 52. Dividends to stockholders 53. Aggregate write-ins for gains and losses in surplus 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,594) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. COLI Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (102,633) (104,145) (386,092) 08.303. Summary of remaining write-ins for Line 8.3 from overflow page (102,633) (104,145) (22,689,690) 08.399. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Geded (20,539,134) (25,891,660) 36,117,501 2702. Finds Withheld Adjustment - Ceded (20,539,134) (25,891,660) 36,117,501 2703. Transfer to IMR - WAB Benef its (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page (562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999		50.1 Paid in			
51. Surplus adjustment: 3,192,201 3,408,944 211,432,030 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance (137,387,518) 100,935,259 (11,054,682) 52. Dividends to stockholders (4,375,905) 179,457 (775,304) 53. Aggregate write-ins for gains and losses in surplus (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (102,633) (104,145) (386,092) 08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IIIR - Ceded (20,539,134) (22,691,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded (6,404,301) 32,463,860 88,531,370 2703. Transfer to IIIR - MVA Benefits (7,167,395) (2,015,112) (22,689,439)		50.2 Transferred from surplus (Stock Dividend)			
51.1 Paid in 3, 192,201 3, 408,944 211,432,030 51.2 Transferred to capital (Stock Dividend) 51.3 Transferred from capital (137,387,518) 100,935,259 (11,054,682) 52. Dividends to stockholders (137,387,518) 100,935,259 (11,054,682) 53. Aggregate write-ins for gains and losses in surplus (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. CULI Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel Ianeous Expense (102,633) (104,145) (386,092) 08.303. (104,145) (386,092) 08.399. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMP - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMP - MVA Benefits (7,167,995) (50.3 Transferred to surplus	ļ		
51.1 Paid in 3, 192,201 3,408,944 211,432,030 51.2 Transferred to capital (Stock Dividend) (137,387,518) 100,935,259 (11,054,682) 51.4 Change in surplus as a result of reinsurance (137,387,518) 100,935,259 (11,054,682) 52. Dividends to stockholders (4,375,905) 179,457 (775,304) 53. Aggregate write-ins for gains and losses in surplus (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. COL1 Income 4,798,747 (4,486,607) 28,655,662 08.303. Miscel Ianeous Expense (102,633) (104,145) (386,092) 08.309. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMP - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded (20,539,134) (25,891,660) 36,117,501 2703. Transfer to IMP - MVA Benefits (7,	51.	Surplus adjustment:			
51.2 Transferred to capital (Stock Dividend) 51.3 Transferred from capital 51.3 Transferred from capital (.137,387,518) .100,935,259 .(11,054,682) 52. Dividends to stockholders (.137,387,518) .100,935,259 .(11,054,682) 52. Dividends to stockholders (.4,375,905) .179,457 .(775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (.100,587,584) .121,579,320 .103,686,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. C0L1 Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (.102,633) (.104,145) (.386,092) 08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (.20,539,134) (.25,891,660) .36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 .32,463,860 .88,531,370 2703. Transfer to IMR - WA Benefits (.7,167,395) (.2,015,112) (.22,689,439) 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (.10,789,			3,192,201	3,408,944	211,432,030
51.3 Transferred from capital 51.4 Change in surplus as a result of reinsurance (137,387,518) 100,935,259 (11,054,682) 52. Dividends to stockholders (4,375,905) 179,457 (775,304) 53. Aggregate write-ins for gains and losses in surplus (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. OLL I Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (102,633) (104,145) (386,092) 08.303. Olimany of remaining write-ins for Line 8.3 from overflow page (102,633) (104,145) (28,695,662) 08.309. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded (20,539,134) (25,891,660) 36,117,501 2703. Transfer to IMR - MVA Benefitis (7,167,395) (2,015,112) (22,689					
51.4 Change in surplus as a result of reinsurance .(137,387,518) .100,935,259 .(11,054,682) 52. Dividends to stockholders					
52. Dividends to stockholders (4,375,905) 179,457 (775,304) 53. Aggregate write-ins for gains and losses in surplus (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. COL1 Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel Ianeous Expense (102,633) (104,145) (386,092) 08.393. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916		51.4 Change in surplus as a result of reinsurance	(137,387,518)	100 935 259	
53. Aggregate write-ins for gains and losses in surplus (4,375,905) 179,457 (775,304) 54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. COLI Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (102,633) (104,145) (386,092) 08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,507 2702. Funds Withheld Adjustment - Ceded (20,539,134) (25,891,660) 36,117,317 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. <td>52</td> <td></td> <td></td> <td></td> <td></td>	52				
54. Net change in capital and surplus for the year (Lines 37 through 53) (100,587,584) 121,579,320 103,586,779 55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. COLI Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (102,633) (104,145) (386,092) 08.393. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (17,751,303) 5302. Athere Re IV Tax Sharing Agreement 54,997 179,457 975,999 5308. Summary of remaining write-ins for Line 53 f					
55. Capital and surplus, as of statement date (Lines 36 + 54) 1,211,646,939 1,330,227,064 1,312,234,523 DETAILS OF WRITE-INS 08.301. COLI Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel laneous Expense (102,633) (104,145) (386,092) 08.303. 08.398. Summary of remaining write-ins for Line 8.3 from overflow page 08.399. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded (20,539,134) (25,891,660) 36,117,501 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement .54,997 179,457 .975,999 53038. Summary of remaining write-ins for Line 53 from overflow page		• • • • • • • • • • • • • • • • • • • •			103 586 770
DETAILS OF WRITE-INS 08.301. COL1 Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel Ianeous Expense (102,633) (104,145) (386,092) 08.303. (8.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 38,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,337,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. Summary of remaining write-ins for Line 53 from overflow page 54,997 179,457 975,999			. , , ,	, ,	
08.301. COLI Income 4,798,747 (4,486,607) 28,655,662 08.302. Miscel Ianeous Expense (102,633) (104,145) (386,092) 08.303. (102,633) (104,145) (386,092) 08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,339 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page 54,997 179,457 975,999	35 .		1,211,040,939	1,000,221,004	1,012,234,523
08.302. Miscel Ianeous Expense (102,633) (104,145) (386,092) 08.303. (08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. Summary of remaining write-ins for Line 53 from overflow page 54,997 179,457 975,999	00		4 700 747	/4 400 00=1	00 055 000
08.303 08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. Summary of remaining write-ins for Line 53 from overflow page 54,997 179,457 975,999					
08.398. Summary of remaining write-ins for Line 8.3 from overflow page 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. Summary of remaining write-ins for Line 53 from overflow page 5398. Summary of remaining write-ins for Line 53 from overflow page 5398. Summary of remaining write-ins for Line 53 from overflow page		·	, , ,	. , ,	, , ,
08.399. Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above) 4,696,115 (4,590,752) 28,269,570 2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. Summary of remaining write-ins for Line 53 from overflow page 5398. Summary of remaining write-ins for Line 53 from overflow page 5398. Summary of remaining write-ins for Line 53 from overflow page					
2701. Transfer to IMR - Ceded (20,539,134) (25,891,660) 36,117,501 2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page 5301 5302 5303 53					
2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page 50,000 10,000 <t< td=""><td></td><td></td><td>, ,</td><td></td><td></td></t<>			, ,		
2702. Funds Withheld Adjustment - Ceded 16,404,301 32,463,860 88,531,370 2703. Transfer to IMR - MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page 50,000 10,000 <t< td=""><td>2701.</td><td>Transfer to IMR - Ceded</td><td>(20,539,134)</td><td>(25,891,660)</td><td>36, 117,501</td></t<>	2701.	Transfer to IMR - Ceded	(20,539,134)	(25,891,660)	36, 117,501
2703. Transfer to IMR – MVA Benefits (7,167,395) (2,015,112) (22,689,439) 2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page 50,000 10,751,303 10,751,303	2702.	Funds Withheld Adjustment - Ceded	16,404,301	32,463,860	88,531,370
2798. Summary of remaining write-ins for Line 27 from overflow page 562,916 85,328 428,331 2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. Summary of remaining write-ins for Line 53 from overflow page 5398. Summary of remaining write-ins for Line 53 from overflow page 54,997 179,457 179,457					
2799. Totals (Lines 2701 through 2703 plus 2798)(Line 27 above) (10,739,312) 4,642,416 102,387,762 5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page					
5301. Correction of Prior Period Error (4,430,902) (1,751,303) 5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page					
5302. Athene Re IV Tax Sharing Agreement 54,997 179,457 975,999 5303. 5398. Summary of remaining write-ins for Line 53 from overflow page			, , , ,	, ,	, ,
5303. Summary of remaining write-ins for Line 53 from overflow page					
5398. Summary of remaining write-ins for Line 53 from overflow page					
5399. Totals (Lines 5301 through 5303 plus 5398)(Line 53 above) (4,3/5,905) 1/9,45/ (775,304)					
	5399.	l otals (Lines 5301 through 5303 plus 5398)(Line 53 above)	(4,3/5,905)	1/9,457	(7/5,304)

CASH FLOW

		Current Year To Date	Prior Year To Date	Prior Year Ended December 31
	Cash from Operations			
1.	Premiums collected net of reinsurance		333,604,352	1,863,430,649
2.	Net investment income	829,059,169	655,856,377	2,603,841,709
3.	Miscellaneous income	216,294,430	154,915,881	798,353,27
4.	Total (Lines 1 to 3)	1,811,280,313	1,144,376,610	5,265,625,63
5.	Benefit and loss related payments	431,957,145	757,090,751	2,350,411,73
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	576,761,113	52,446,834	692,992,89
7.	Commissions, expenses paid and aggregate write-ins for deductions	244,140,086	186,306,178	891,078,74
8.	Dividends paid to policyholders		(292)	(292
9.	Federal and foreign income taxes paid (recovered) net of \$23,261,016 tax on capital			
	gains (losses)	4,540,353	4,859,895	81,768,05
10.	Total (Lines 5 through 9)	1,257,398,697	1,000,703,367	4,016,251,13
11.	Net cash from operations (Line 4 minus Line 10)	553,881,616	143.673.243	1,249,374,50
	101 000 100 000 000 000 000 000 000 000	300,00.,0.0	,,	1,210,011,00
	Cash from Investments			
12.	Proceeds from investments sold, matured or repaid:			
	12.1 Bonds	1,377,657,398	2,479,658,207	6,550,765,03
	12.2 Stocks	29,907,039	4,000,408	52,361,43
	12.3 Mortgage loans		712,932,632	3,233,345,63
	12.4 Real estate		4,866	
	12.5 Other invested assets	123, 102, 186	55,973,627	416,633,20
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	(4,003,562)	(1,988,572)	6,324,89
	12.7 Miscellaneous proceeds	386,674,383	154,777,622	45,394,53
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		3,405,358,789	
13.	Cost of investments acquired (long-term only):			
10.	13.1 Bonds	4 072 079 290	1 517 205 105	0 001 020 57
	13.2 Stocks			
	13.3 Mortgage loans		857,729,319	
	13.4 Real estate			
	13.5 Other invested assets			
	13.6 Miscellaneous applications	, ,	13,060,399	217, 159, 705
	13.7 Total investments acquired (Lines 13.1 to 13.6)	6,562,735,773	2,533,328,203	12,666,878,263
14.	Net increase (or decrease) in contract loans and premium notes	(5,230,386)	(8,483,785)	(18,110,168
15.	Net cash from investments (Line 12.8 minus Line 13.7 and Line 14)	(4,399,607,245)	880,514,371	(2,343,938,48
	Cash from Financing and Miscellaneous Sources			
16.	Cash provided (applied):			
	16.1 Surplus notes, capital notes			
	16.2 Capital and paid in surplus, less treasury stock			
	16.3 Borrowed funds			
	16.4 Net deposits on deposit-type contracts and other insurance liabilities			
	16.5 Dividends to stockholders			
	16.6 Other cash provided (applied)		(404,473,327)	
17.		00,414,721	(404,470,027)	107,007,01
17.	plus Line 16.6)	3,103,870,378	(415,393,967)	2,077,371,876
4-	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	(744 055 054)	000 700 040	000 007 00
18.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(741,855,251)	608,793,646	982,807,89
	Cash, cash equivalents and short-term investments:			
		3,807,048,181	2,824,240,288	2,824,240,28
	19.1 Beginning of year		3,433,033,934	3,807,048,18
	19.1 Beginning of year	3,065,192,930	3,403,000,904	
19.		3,065,192,930	3,433,033,334	
19. e: Su	19.2 End of period (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 01. Capital contribution of stock compensation expense (financing)	3, 192, 201	3,408,944	
e: St 0.000	19.2 End of period (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 01. Capital contribution of stock compensation expense (financing) 02. Capital contribution of stock compensation expense (investing)	3,192,201(200,958)	3,408,944	(688,68
e: Si 0.000 0.000 0.000	19.2 End of period (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 01. Capital contribution of stock compensation expense (financing) 02. Capital contribution of stock compensation expense (investing) 03. Capital contribution of stock compensation expense (operating) 04. Security exchanges and asset in kind trades – bond proceeds (investing)	3,192,201(200,958)(2,991,243)189,928,387	3,408,944 (164,501) (3,244,443) 639,431,022	(688,68 (10,743,34 2,460,700,00
19. te: St 0.000 0.000 0.000 0.000 0.000	19.2 End of period (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 01. Capital contribution of stock compensation expense (financing) 02. Capital contribution of stock compensation expense (investing) 03. Capital contribution of stock compensation expense (operating) 04. Security exchanges and asset in kind trades – bond proceeds (investing) 05. Security exchanges and asset in kind trades – bonds acquired (investing)			(688,68 (10,743,34 2,460,700,00 (2,460,700,00
te: St 0.000 0.000 0.000 0.000	upplemental disclosures of cash flow information for non-cash transactions: 01. Capital contribution of stock compensation expense (financing) 02. Capital contribution of stock compensation expense (investing) 03. Capital contribution of stock compensation expense (investing) 04. Security exchanges and asset in kind trades – bond proceeds (investing) 05. Security exchanges and asset in kind trades – bonds acquired (investing) 06. Reinsurance activity settled in bonds (operating)	3, 192,201 (200,958) (2,991,243) (189,928,387 (189,928,387) 176,663,459	3,408,944 (164,501) (3,244,443) .639,431,022 .(639,431,022) .15,939,205	
19. te: Su 20.000 20.000 20.000 20.000 20.000 20.000 20.000	19.2 End of period (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 01. Capital contribution of stock compensation expense (financing) 02. Capital contribution of stock compensation expense (investing) 03. Capital contribution of stock compensation expense (operating) 04. Security exchanges and asset in kind trades – bond proceeds (investing) 05. Security exchanges and asset in kind trades – bonds acquired (investing)	3, 192,201 (200,958) (2,991,243) (189,928,387) (189,928,387) (176,663,459) (176,663,459) (43,000,000)	3,408,944 (164,501) (3,244,443) .639,431,022 (639,431,022) (15,939,205) (15,939,205)	(688, 68 (10, 743, 34 2, 460, 700, 00 (2, 460, 700, 00

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0011. Interest capitalization (investing)	 (1,397,744)	(8,050,361)
20.0012. Transfer from Schedule B to Schedule BA - proceeds (investing)		218,610,865
20.0013. Transfer from Schedule B to Schedule BA - acquired (investing)	 (1,299,408)	(218,610,865)
20.0014. Security exchanges and asset in kind trades - stocks acquired (investing)	 	(1,716,696)
20.0015. Security exchanges and asset in kind trades - stock proceeds (investing)	 	1,714,400

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of **Athene Annuity and Life Company** (the Company) have been prepared in conformity with the accounting practices prescribed or permitted by the National Association of Insurance Commissioners (NAIC) and the State of Iowa.

The Insurance Division, Department of Commerce, of the State of Iowa (the Division) recognizes only statutory accounting practices prescribed or permitted by the State of Iowa for determining and reporting the financial condition and results of operations of an insurance company and for determining its solvency under the Iowa Insurance Law. The NAIC's Accounting Practices & Procedures Manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Iowa. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices.

Among the products issued by the Company are indexed universal life insurance and indexed annuities. These products allow a portion of the premium to earn interest based on certain indices, such as the Standard & Poor's 500 Composite Stock Price Index. Call options, futures, variance swaps and total return swaps are purchased to hedge the growth in interest credited to the customer as a direct result of increases in the related indices. In 2006, the Commissioner of the Division issued Bulletin 06-01, *Accounting for Derivative Instruments Used to Hedge the Growth in Interest Credited for Index Products*, which prescribes that an insurer may elect to recognize changes in the fair value of derivative instruments purchased to hedge indexed products in the statement of operations. The Company has elected to apply Bulletin 06-01 to its futures, variance swaps and total return swaps, which resulted in a decrease of \$2.0 million and increase of \$5.0 million to the Company's net income for the three months ended March 31, 2021 and for the year ended December 31, 2020, respectively. Application of Bulletin 06-01 does not impact the Company's statutory surplus amounts.

In 2009, the Commissioner of the Division promulgated Iowa Administrative Code (IAC) Section 191-97, Accounting for Certain Derivative Instruments Used to Hedge the Growth in Interest Credited for Indexed Insurance Products and Accounting for the Indexed Insurance Products Reserve, which prescribes that an insurer may elect (i) to use an amortized cost method to account for certain derivative instruments, such as call options, purchased to hedge the growth in interest credited to the customer on indexed insurance products and (ii) to utilize an indexed annuity reserve calculation methodology under which call options associated with the current index interest crediting term are valued at zero. IAC Section 191-97 does not apply to products that do not guarantee a minimum interest accumulation, such as our variable and index-liked deferred annuities. The Company has elected to apply IAC Section 191-97 to its eligible over the counter (OTC) call options and reserve liabilities. As a result, the Company's net income increased by \$11.3 million and \$19.6 million for the three months ended March 31, 2021 and for the year ended December 31, 2020, respectively, and the Company's statutory surplus decreased by \$82.7 million and \$83.8 million as of March 31, 2021 and December 31, 2020, respectively.

The NAIC requires annuities issued by life insurance companies on or after January 1, 2015, to use the 2012 Individual Annuity Reserving (IAR) Mortality Table. In 2015, the Division promulgated IAC Section 43.3(5), which set an elective alternative effective date of January 1, 2016 for adoption of the 2012 IAR Mortality Table. The Company chose to use the Annuity 2000 Mortality Table for all annuities issued in 2015, which resulted in an increase of \$0.4 million to the Company's net income for both the three months ended March 31, 2021 and the year ended December 31, 2020. The Company's statutory surplus increased by \$5.7 million and \$5.3 million as of March 31, 2021 and December 31, 2020, respectively.

A reconciliation of the Company's net income and statutory surplus between practices prescribed or permitted by the State of Iowa and NAIC SAP is shown below:

	SSAP#	F/S Page	F/S Line #	03/31/2021	12/31/2020
Net Income					
(1) State basis (Page 4, Line 35, Columns 1 & 3)	XXX	XXX	XXX	\$ 32,565,509	\$(7,963,713)
(2) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
Derivative Instruments Bulletin 06-01	86	4	38	(2,031,616)	4,966,262
Derivative Instruments and Equity Indexed Reserves IAC 191-97	86, 51	2, 3	7, 1	11,287,733	19,584,793
2012 IAR Mortality Table for Annuities Issued in 2015 IAC 43.3(5)	51	3	1	357,664	370,839
(3) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 22,951,728	\$ (32,885,607)
Surplus					
(5) State basis (Page 3, Line 38, Columns 1 & 2)	XXX	XXX	XXX	\$ 1,211,646,939	\$ 1,312,234,523
(6) State prescribed practices that are an increase / (decrease) from NAIC SAP:					
Derivative Instruments and Equity Indexed Reserves IAC 191-97	86, 51	2, 3	7, 1	(82,659,725)	(83,808,046)
2012 IAR Mortality Table for Annuities Issued 2005 IAC 43.3(5)	51	3	1	5,656,715	5,299,051
(7) State permitted practices that are an increase / (decrease) from NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 1,288,649,949	\$ 1,390,743,518

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC SAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the period. There are material risks and uncertainties surrounding the spread of the Coronavirus Disease of 2019 (COVID-19), which has resulted in significant volatility in the financial markets. Our estimates may vary as more information about the extent to which COVID-19 and the resulting impact on economic conditions and the financial markets become known. Actual results may differ from the estimates used in preparing the financial statements.

C. Accounting Policy

(1) Short-term investments - No Significant Changes

1. Summary of Significant Accounting Policies and Going Concern (Continued)

- (2) Bonds, other than loan-backed and structured securities, are stated at amortized cost or fair value based on their rating by the NAIC. Bonds held at amortized cost are amortized using the scientific interest method on a yield-to-worst basis.
- (3) Common stocks No Significant Changes
- (4) Effective January 1, 2021, the Company adopted the revised guidance in SSAP No. 32R, *Preferred Stock*, which requires perpetual preferred stock to be carried at fair value, not to exceed any currently effective call price. Prior to 2021, perpetual preferred stock with an NAIC designation 1-3 was valued at cost, and perpetual preferred stock with an NAIC designation 4-6 was valued at the lower of cost or fair value. The adoption did not have a material effect on the Company's financial statements.
- (5) Mortgage loans No Significant Changes
- (6) Loan-backed and structured securities are stated at amortized cost or fair market value based on their rating by the NAIC. Changes to estimated cash flows on the securities are accounted for retrospectively for securities that are highly rated at the time of purchase and in which the security cannot be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. The prospective method is used for those securities where an other than temporary impairment has been taken, the security is not highly rated at the time of purchase, securities where receipt of all contractual principal cash flows is not expected, or those securities that can be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. Loan-backed and structured securities stated at amortized cost are amortized or accreted using the scientific interest method.
- (7) Investments in subsidiaries, controlled and affiliated entities No Significant Changes
- (8) Investments in joint ventures, partnerships and limited liability entities No Significant Changes
- (9) Derivatives No Significant Changes
- (10) Investment income as a factor in the premium deficiency calculation No Significant Changes
- (11) Liabilities for losses and loss/claim adjustment expenses No Significant Changes
- (12) Changes in capitalization policy No Significant Changes
- (13) Pharmaceutical rebate receivables No Significant Changes

D. Going Concern

Management's assessment of the relevant conditions through May 13, 2021 does not give rise to substantial doubt of the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

During the current year's financial statement preparation, the Company was notified by Accordia Life and Annuity Company of certain life insurance policies novated by them in error. This resulted in an overstatement of the Company's A-791 amortization in prior Annual Statements. After consideration of materiality and in accordance with SSAP No. 3 *Accounting Changes and Correction of Errors*, the correction was recorded directly to surplus. The impact of the correction of A-791 amortization represented a reclassification of \$4.4 million between income and surplus, with no net impact to surplus.

3. Business Combinations and Goodwill - No Significant Changes

4. Discontinued Operations - None

5. Investments

- A. Mortgage Loans, including Mezzanine Real Estate Loans No Significant Changes
- B. Debt Restructuring No Significant Changes
- C. Reverse Mortgages None
- D. Loan-Backed Securities
 - (1) Prepayment assumptions for loan-backed bonds and structured securities were obtained from broker dealer survey values or internal estimates.
 - (2) Loan-backed and structured securities with a recognized other-than-temporary impairment (OTTI)

No other-than-temporary impairment was recognized on loan-backed securities due to the intent to sell or inability or lack of intent to retain the investment for a period of time sufficient to recover the amortized cost basis.

(3) Securities held that were other-than-temporarily impaired due to the present value of cash flows expected to be collected was less than the amortized cost of securities

(1)	(2)	(3)	(4)	(5)	(6)	(7)
CUSIP	Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	Present Value of Projected Cash Flows	Recognized OTTI	Amortized Cost After OTTI	Fair Value at Time of OTTI	Date of Financial Statement Where Reported
007037AB0	\$ 2,222,762	\$ 2,186,681	. \$ 36,081	\$ 2,186,681	\$ 2,140,833	03/31/2021
61748HVH1	2,308,833	2,275,891	32,943	2,275,891	2,139,886	03/31/2021
885220DS9	787,329	715,083	72,245	715,083	634,565	03/31/2021
41161PWC3	2,002,754	1,973,691	29,063	1,973,691	1,924,030	03/31/2021
Total			\$ 170,333			

(4) All impaired securities for which an OTTI has not been recognized in earnings as a realized loss

The following table shows the gross unrealized losses and fair values of loan-backed securities, which have not been impaired to fair value, aggregated by length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2021:

Investments (Continued)

- a. The aggregate amount of unrealized losses: 1. Less than 12 months...... ... \$..... 77,574,594 2. 12 months or longer... 92,713,347 b. The aggregate related fair value of securities with unrealized losses:
- 1. Less than 12 months... \$ 5,115,539,946
 - 2. 12 months or longer. .. 1.928.083.933
- (5) A full analysis of all relevant qualitative considerations was completed in reaching the conclusion that the impairments were not otherthan-temporary, including the intent and ability to hold the investment for a period of time sufficient to allow for a recovery in value. Specific events that may influence the operations of the issuer and impaired earnings potential are reviewed in addition to length of time and extent to which the fair value has been less than cost.
- Dollar Repurchase Agreements and/or Securities Lending Transactions None
- Repurchase Agreements Transactions Accounted for as Secured Borrowing

Repurchase Transaction - Cash Taker - Overview of Secured Borrowing Transactions

(1) Information regarding the company policy or strategies for engaging in repo programs, policy for requiring collateral

The Company participates in repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company lends bonds and receives cash as collateral. The Company monitors the estimated fair value of the collateral and the securities loaned throughout the duration of the contract and contributes additional collateral as necessary. Securities loaned under these agreements may be sold or re-pledged by the transferee.

(2) Type of repo trades used

			Second		Fourth
		First Quarter	Quarter	Third Quarter	Quarter
a.	Bilateral (Yes/No)	YES			
b.	Tri-Party (Yes/No)	NO			

(3) C

Origin	al (flow) & residual maturity				
			First Quarter	Second Quarter	Third Quarter	Fourth Quarter
a.	Maxir	mum Amount				
	1.	Open - No maturity	\$	\$	\$	\$
	2.	Overnight				
	3.	2 days to 1 week				
	4.	Over 1 week to 1 month				
	5.	Over 1 month to 3 months				
	6.	Over 3 months to 1 year				
	7.	Over 1 year	598,651,804			
b.	Endin	g Balance				
	1.	Open - No maturity	\$	\$	\$	\$
	2.	Overnight				
	3.	2 days to 1 week				
	4.	Over 1 week to 1 month				
	5.	Over 1 month to 3 months				
	6.	Over 3 months to 1 year				
	7.	Over 1 year	598,651,804			

(4) Fair value of securities sold and/or acquired that resulted in default

The Company did not have any securities sold or outstanding for which the repurchase agreement defaulted as of March 31, 2021.

(5) Securities "sold" under repo - secured borrowing

				Second		
			First Quarter	Quarter	Third Quarter	Fourth Quarter
a.	Max	imum Amount				
	1.	BACV	XXX	XXX	XXX	\$
	2.	Nonadmitted - Subset of BACV	XXX	XXX	XXX	\$
	3.	Fair Value	\$ 716,793,655 \$	\$	\$	\$
b.	Endi	ng Balance				
	1.	BACV	XXX	XXX	XXX	\$
	2.	Nonadmitted - Subset of BACV	XXX	XXX	XXX	\$
	3.	Fair Value	\$ 716,793,655 \$	3	\$	\$

5. Investments (Continued)

(6) Securities sold under repo - secured borrowing by NAIC designation

	Ending Balance	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
		None	NAIC 1	NAIC 2	NAIC 3	NAIC 4	NAIC 5	NAIC 6	Nonadmitted
a.	Bonds - BACV	\$	\$ 207,899,985	\$ 441,815,607	\$	\$	\$	\$	\$
b.	Bonds - FV		230,922,589	485,871,066					
C.	LB & SS - BACV								
d.	LB & SS - FV								
e.	Preferred stock - BACV								
f.	Preferred stock - FV								
g.	Common stock								
h.	Mortgage loans - BACV								
i.	Mortgage loans - FV								
j.	Real estate - BACV								
k.	Real estate - FV								
I.	Derivatives - BACV								
m.	Derivatives - FV								
n.	Other invested assets - BACV								
0.	Other invested assets - FV								
p.	Total assets - BACV	\$	\$ 207,899,985	\$ 441,815,607	\$	\$	\$	\$	\$
q.	Total assets - FV	\$	\$ 230,922,589	\$ 485,871,066	\$	\$	\$	\$	\$

p = (a+c+e+g+h+j+l+n)

(7) Collateral received - secured borrowing

					_ Fir	st Quarter	Second Quarter	Third Quarter	Fourth Quarter
a.	Maxir	num Amount							
	1.	Cash			\$\$	598,651,804	\$	\$	\$
	2.	Securities (FV)							
b.	Endin	g Balance							
	1.	Cash			\$\$	598,651,804	\$	\$	\$
	2.	Securities (FV)							
(8) Cash	& non-ca	ash collateral receive	d - secured bor	rowing by NAIC	designation				
Ending Balance		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)

	Ending Balance	(1)	(1) (2) (3) (4)		(5)	(6)	(7)	(8)	
		None	NAIC 1	NAIC 2	NAIC 3	NAIC 4	NAIC 5	NAIC 6	Does Not Qualify as Admitted
a.	Cash	\$ 598,651,804	\$	\$	\$	\$	\$	\$	\$
b.	Bonds - FV								
C.	LB & SS - FV								
d.	Preferred stock - FV								
e.	Common stock								
f.	Mortgage loans - FV								
g.	Real estate - FV								
h.	Derivatives - FV								
i.	and the second								
j.	Total collateral assets - FV (sum of a through i)	\$ 598,651,804	\$	\$	\$	\$	\$	\$	\$

(9) Allocation of aggregate collateral by remaining contractual maturity

		Fair Value
a.	Overnight and continuous	\$
b.	30 Days or less	
C.	31 to 90 Days	
d.	More than 90 days	598,651,804

q = (b+d+f+g+i+k+m+o)

5. Investments (Continued)

(10) Allocation of aggregate collateral reinvested by remaining contractual maturity

		Amortized Cost	Fair Value
a.	30 Days or less	\$. 598,651,804	\$. 598,651,804
b.	31 to 60 Days		
C.	61 to 90 Days		
d.	91 to 120 Days		
e.	121 to 180 Days		
f.	181 to 365 Days		
g.	1 to 2 Years		
h.	2 to 3 Years		
i.	More than 3 years		

(11) Liability to return collateral - secured borrowing (total)

		F	irst Quarter	Second Quarter	Third Quarter	Fourth Quarter
a.	Max	ximum Amount				
	1.	Cash (Collateral - All)\$	598,651,804	\$	\$	\$
	2.	Securities Collateral (FV)				
b.	Endi	ing Balance				
	1.	Cash (Collateral - All)\$	598,651,804	\$	\$	\$
	2.	Securities Collateral (FV)				

- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing None
- H. Repurchase Agreements Transactions Accounted for as a Sale None
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale None
- J. Real Estate No Significant Changes
- K. Low-Income Housing Tax Credits (LIHTC) None
- L. Restricted Assets No Significant Changes
- M. Working Capital Finance Investments None
- N. Offsetting and Netting of Assets and Liabilities None
- O. 5GI Securities No Significant Changes
- P. Short Sales None
- Q. Prepayment Penalty and Acceleration Fees No Significant Changes
- R. Reporting Entity's Share of Cash Pool by Asset type None
- 6. Joint Ventures, Partnerships and Limited Liability Companies No Significant Changes
- 7. Investment Income No Significant Changes
- 8. Derivative Instruments
 - A. Derivatives under SSAP No. 86 Derivatives
 - (1) Discussion No Significant Changes
 - (2) Description of objectives No Significant Changes
 - (3) Description of accounting policies No Significant Changes
 - (4) Derivative contracts with financing premiums No Significant Changes
 - (5) Net gain or loss recognized No Significant Changes
 - (6) Net gain or loss recognized from derivatives no longer qualifying for hedge accounting No Significant Changes
 - (7) Derivatives accounted for as cash flow hedges of a forecasted transaction No Significant Changes
 - (8) Premium Cost for Derivative Contracts None
 - B. Derivatives under SSAP No. 108 Derivative Hedging Variable Annuity Guarantees (Life/Fraternal Only) None
- 9. Income Taxes No Significant Changes

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. On March 8, 2021, Athene Holding Ltd. (AHL), an indirect parent of the Company, entered into an Agreement and Plan of Merger (Merger Agreement), by and among AHL, Apollo Global Management, Inc., a Delaware corporation (AGM), Tango Holdings, Inc., a Delaware corporation and a direct wholly owned subsidiary of AGM (HoldCo), Blue Merger Sub, Ltd., a Bermuda exempted company and a direct wholly owned subsidiary of HoldCo (AHL Merger Sub), and Green Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of HoldCo (AGM Merger Sub). AHL and AGM have agreed, subject to the terms and conditions of the Merger Agreement, to effect an all-stock merger transaction to combine the respective businesses by: (1) AGM merging with AGM Merger Sub, with AGM surviving such merger as a direct wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AHL Merger Sub, with AHL surviving such merger as a direct, wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merging with AGM Merger, Mergers), and (3) as of the effective time of the Mergers, changing the name of HoldCo (AGM Merger), (2) AHL merging with AGM Merger Sub, with AGM surviving such merger as a direct wholly owned subsidiary of HoldCo (AGM Merger), (2) AHL merger Sub, Inc.,

Some employees of the Company and Athene Employee Services LLC participate in one or more Share Award Agreements (the Agreements) sponsored by AHL for which the Company has no legal obligation. Salary expense of the Company and of Athene Employee Services LLC is allocated through the Shared Services Agreement. Under SSAP No. 104R, *Share-Based Payments*, the stock compensation expense associated with the Agreements that would have been allocated to the Company is required to be recorded as a capital contribution to the reporting entity. The Company has allocated the stock compensation expense associated with the Agreements based on the same methodology as the Shared Services Agreement. In accordance with SSAP No. 104R, the Company incurred expense and recorded a capital contribution under the Agreements totaling \$3.2 million and \$11.4 million for the three months ended March 31, 2021 and for the year ended December 31, 2020, respectively, which includes amounts contributed by the Company to downstream insurance subsidiaries.

- B. Detail of Related Party Transactions No Significant Changes
- C. Transactions With Related Party Who Are Not Reported on Schedule Y No Significant Changes
- D. Amounts Due To or From Related Parties No Significant Changes
- E. Management Service Contracts and Cost Sharing Arrangements No Significant Changes
- F. Guarantees or Contingencies No Significant Changes
- G. Nature of Relationships that Could Affect Operations No Significant Changes
- H. Amount Deducted for Investment in Upstream Company None
- I. Detail of Investments in Affiliates Greater Than 10% of Admitted Assets No Significant Changes
- J. Write-Down for Impairments of Investments in Subsidiary Controlled or Affiliated Companies No Significant Changes
- K. Foreign Subsidiary Value Using CARVM No Significant Changes
- L. Downstream Holding Company Value Using Look-Through Method No Significant Changes
- M. All SCA Investments No Significant Changes
- N. Investment in Insurance SCAs No Significant Changes
- O. SCA and SSAP No. 48 Entity Loss Tracking None

11. Debt

- A. Debt. Including Capital Notes No Significant Changes
- B. FHLB (Federal Home Loan Bank) Agreements
 - (1) The Company is a member of the FHLB of Des Moines. Through its membership, the Company is eligible to borrow under variable rate short-term federal fund arrangements to provide additional liquidity. These borrowings are accounted for as borrowed money under SSAP No. 15, *Debt and Holding Company Obligations*. The Company did not have any outstanding borrowings as of March 31, 2021 or December 31, 2020. The Company incurred interest expense on short-term borrowings of \$0 and \$2.7 million in the general and separate account for the three months ended March 31, 2021 and for the year ended December 31, 2020, respectively.

The Company has issued separate account funding agreements to the FHLB of Des Moines in exchange for cash resulting in a liability of \$1,919.3 million as of March 31, 2021. The Company uses these funds in an investment spread strategy, consistent with its other investment spread operations. As such, the Company applies SSAP No. 52, *Deposit-Type Contracts*, accounting treatment to these funds, consistent with its other deposit-type contracts. It is not part of the Company's strategy to utilize these funds for operations, and any funds obtained from the FHLB of Des Moines for use in general operations would be accounted for consistent with SSAP No. 15 as borrowed money.

The Company must provide appropriate collateral to borrow under the arrangements described above. The borrowing capacity available to the Company under these agreements is largely a factor of the Company's ability to post eligible collateral, as well as internal limits such as single-holder exposure limits (10% of the entity's balance sheet liabilities) and NAIC capital requirements.

The tables below indicate the amount of FHLB of Des Moines stock purchased, collateral pledged, assets and liabilities related to the agreements with FHLB of Des Moines.

11. Debt (Continued)

FHLB capital stock	(2)	FHLB	capital	stock
--------------------------------------	-----	------	---------	-------

(a) Aggregate to	otals
(~	, rigginggate to	otaio

							(1 Tot (2+	al	(2) General Account	(3) Separate Accounts
	1.	Current Year								
		(a) Membership sto	ock - Class A				\$		\$	\$
		(b) Membership sto	ock - Class B				10,0	000,000	10,000,0	000
		(c) Activity stock					80,0	148,000	80,048,0	000
		· /								
		(e) Aggregate total	(a+b+c+d)				\$ 90,0	148,000	\$ 90,048,0	000 \$
		(f) Actual or estimate	ated borrowing capa	city as determined	by the insu	urer	\$ 3,200,0	000,000		
	2.	Prior Year-End								
		(a) Member stock -	Class A				\$		\$	\$
		(b) Membership sto	ock - Class B				10,0	000,000	10,000,0	000
		* *								
			(a+b+c+d)						\$ 90,048,0	000 \$
		(f) Actual or estimate	ated borrowing capa	city as determined	by the insu	urer	\$ 3,200,0	000,000		
(b)	iviei	nbership stock (class	(1)	(2)	(3)		Eligible	for Red	emption (5)	(6)
	Me	mbership Stock	Current Year Total (2+3+4+5+6)	Not Eligible for Redemption	Less Tha Month		6 Months to L Than 1 Yea		o Less Than Years	3 to 5 Years
		Class A								
	2.	Class B	\$ 10,000,000	\$ 10,000,000 .	\$		\$	\$		\$
) Coll	atera	al pledged to FHLB								
(a)	Amo	ount pledged as of re	eporting date							
(4)	,	ount prouged do or re	porting date							
							(1)		(2)	(3)
							Fair Value	Carry	ing Value	Aggregate Total Borrowing
	1.	Current year total ge								
	2.		account total collater							
	3.	, ,	e accounts total colla							2,001,200,000
	4.		general and separate a				3,074,082,334		2,931,251,265	2,001,200,000
(b)	Max	kimum amount pledg	jed during reporting រុ	period						
							(1)		(2)	(3)
							(.)		(-)	Amount Borrowed at Time of
							Fair Value	Carry	ing Value	Maximum Collateral
	1.	Current year total ge pledged (Lines 2+3).	neral and separate ac			\$	3,074,082,334	\$	2,931,251,265	\$ 2,001,200,000
	2.	Current year general	account maximum co	ollateral pledged			3,074,082,334		2,931,251,265	
	3.	Current year separat	e accounts maximum	collateral pledged.						2,001,200,000
	4.		general and separate a				3,074,082,334		2,931,251,265	2,001,200,000

11. Debt (Continued)

- (4) Borrowing from FHLB
 - (a) Amount as of the reporting date

		(1)	(2)	(3)	(4)
		Total (2+3)	General Account	Separate Accounts	Funding Agreements Reserves Established
1.	Current Year				
	(a) Debt	\$	\$	\$	XXX
	(b) Funding agreements	2,001,200,000		2,001,200,000	\$ 1,919,322,986
	(c) Other				XXX
	(d) Aggregate total (a+b+c)	\$ 2,001,200,000	\$	\$ 2,001,200,000	\$ 1,919,322,986
2.	Prior Year-end				
	(a) Debt	\$	\$	\$	XXX
	(b) Funding agreements	2,001,200,000		2,001,200,000	\$ 1,914,668,450
	(c) Other				XXX
	(d) Aggregate total (a+b+c)	\$ 2,001,200,000	\$	\$ 2,001,200,000	\$ 1,914,668,450

(b) Maximum amount during reporting period (current year)

		(1) Total (2+3)	(2) General Account	(3) Separate Accounts
1.	Debt	\$	\$	\$
2.	Funding agreements	2,001,200,000		2,001,200,000
3.	Other			
4.	Aggregate total (Lines 1+2+3)	\$ 2,001,200,000	\$	\$ 2,001,200,000

11B(4)b4 (Columns 1, 2 and 3) should be equal to or greater than 11B(4)a1(d) (Columns 1, 2 and 3 respectively)

(c) FHLB - Prepayment obligations

Does the company have prepayment obligations under the following arrangements (YES/NO)?

		<u> </u>
1.	Debt	NO
2.	Funding agreements	YES
3.	Other	NO

- 12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans No Significant Changes
- 13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations No Significant Changes
- 14. Liabilities, Contingencies and Assessments
 - A. Contingent Commitments No Significant Changes
 - B. Assessments No Significant Changes
 - C. Gain Contingencies None
 - D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits None
 - E. Joint and Several Liabilities None

14. Liabilities, Contingencies and Assessments (Continued)

F. All Other Contingencies

Corporate-owned Life Insurance (COLI) Matter - In 2000 and 2001, two insurance companies which were subsequently merged into the Company, purchased broad based variable COLI policies from American General Life Insurance Company (American General) that, as of March 31, 2021, had an asset value of \$413.3 million, and is included as an admitted asset on the balance sheets. In January 2012, the COLI policy administrator delivered to the Company a supplement to the existing COLI policies and advised that American General and ZC Resource Investment Trust (ZC Trust) had unilaterally implemented changes set forth in the supplement that if effective, would: (1) potentially negatively impact the crediting rate for the policies and (2) change the exit and surrender protocols set forth in the policies. In March 2013, the Company filed suit against American General, ZC Trust, and ZC Resource LLC in Chancery Court in Delaware, seeking, among other relief, a declaration that the changes set forth in the supplement were ineffectual and in breach of the parties' agreement. The parties filed cross motions for judgment as a matter of law, and the court granted defendants' motion and dismissed without prejudice on ripeness grounds. The issue that negatively impacts the crediting rate for one of the COLI policies has subsequently been triggered and on April 3, 2018, we filed suit against the same defendants in Chancery Court in Delaware seeking substantially similar relief. Defendants moved to dismiss and the Court heard oral arguments on February 13, 2019. The Court issued an opinion on July 31, 2019 that did not address the merits, but found that Chancery Court defined have jurisdiction over our claims and directed us to either amend our complaint or transfer the matter to Delaware Superior Court. The matter has been transferred to the Delaware Superior Court. Defendants renewed their motion to dismiss and the Superior Court heard oral arguments on December 18, 2019. The Superior Court issued an opinion on May 18, 2020 in which i

Regulatory Matters - The Company and certain of its insurance subsidiaries have experienced increased complaints related to the conversion and administration of the block of life insurance business acquired in connection with Athene Holding Ltd.'s acquisition of Aviva USA Corporation (Aviva USA) and reinsured to affiliates of Global Atlantic Financial Group Ltd. The life insurance policies included in this block have been and are currently being administered by AllianceOne, a subsidiary of DXC Technology Company, which was retained by such Global Atlantic affiliates to provide third party administration services on such policies. AllianceOne also administers a small block of annuity policies that were on Aviva USA's legacy policy administration systems that were also converted in connection with the acquisition of Aviva USA and have experienced similar service and administration issues, but to a lesser degree.

As a result of the difficulties experienced with respect to the administration of such policies, the Company and its subsidiary, Athene Life Insurance Company of New York (ALICNY), have received notifications from several state regulators, including but not limited to the New York State Department of Financial Services (NYDFS), the California Department of Insurance (CDI) and the Texas Department of Insurance (TDI), indicating, in each case, that the respective regulator planned to undertake a market conduct examination or enforcement proceeding of the Company or one of its subsidiaries, as applicable, relating to the treatment of policyholders subject to the Company's reinsurance agreements with affiliates of Global Atlantic and the conversion of the life and annuity policies, including the administration of such blocks by AllianceOne. The Company and ALICNY have entered into consent orders with regulators of several states, including the NYDFS, the CDI, and the TDI, to resolve the underlying matters in the respective states. All fines and costs, including those associated with remediation plans, paid in connection with the consent orders were subject to indemnification by Global Atlantic or affiliates of Global Atlantic.

In addition to the examinations and proceedings initiated to date, it is possible that other regulators may pursue similar formal examinations, inquiries or enforcement proceedings and that any examinations, inquiries and/or enforcement proceedings may result in fines, administrative penalties and payments to policyholders. The Company is not currently able to estimate the amount of any such fines, penalties or payments arising from these matters with reasonable certainty, but it is possible that such amounts may be material.

Pursuant to the terms of the reinsurance agreements between the Company and the relevant affiliates of Global Atlantic, the applicable affiliates of Global Atlantic have financial responsibility for the ceded life block and are subject to significant administrative service requirements, including compliance with applicable law. The agreements also provide for indemnification to the Company, including for administration issues.

Fiduciary Standards - The U.S. Securities and Exchange Commission (SEC), Department of Labor (DOL), NAIC, and several states have taken action or are exploring options around a fiduciary standard or best interest standard that may impact the Company and its subsidiaries. If these rules do not align, the distribution of products by the Company and its subsidiaries could be further complicated.

On June 5, 2019, the SEC adopted a rulemaking package designed to enhance the quality and transparency of retail investors' relationships with investment advisers and broker-dealers. The rule package is effective on September 10, 2019 with a compliance date of June 30, 2020. The rulemaking package included: Regulation Best Interest - the Broker-Dealer Standard of Conduct; the new Form CRS Relationship Summary; and two separate interpretations under the Investment Advisers Act of 1940. The Company believe the Regulation may impact the distribution of the Company's and its subsidiaries' products through third party broker-dealers that distribute the products to retail customers, the impact of which is still being determined.

The NAIC has adopted the Suitability in Annuity Transactions Model Regulation (SAT), which places responsibilities upon issuing insurance companies with respect to the suitability of annuity sales, including responsibilities for training agents. Many states, including Athene Domiciliary States, have already enacted laws and/or regulations based on SAT, thus imposing suitability standards with respect to sales of FIAs. The NYDFS issued a circular letter emphasizing insurers' obligations under laws and regulations based on SAT when replacing a deferred annuity contract with an immediate annuity contract. On July 22, 2018, the NYDFS issued amendments to its regulation based on SAT to incorporate a "best interest" standard with respect to the suitability of life insurance and annuity sales, which amendments took effect on August 1, 2019 with respect to annuity contracts and became effective on February 1, 2020 with respect to life insurance policies. Future changes in such laws and regulations, including those that impose a "best interest" standard could adversely impact the way we market and sell our annuity products. On February 13, 2020, the NAIC adopted amendments to the SAT to incorporate a "best interest" or similar standard with respect to the suitability of annuity sales. The amendments include a requirement for producers to act in the "best interest" of a retail customer when making a recommendation of an annuity. A producer is considered to have acted in the best interest of the customer if they have satisfied certain prescribed obligations regarding care, disclosure, conflict of interest and documentation. State adoption of these revisions, and any future changes in such laws and regulations, could adversely affect the way our US insurance subsidiaries market and sell their annuity products. Several states, including lowa, have adopted or are in the process of adopting a version of the revised SAT that includes a best interest concent.

14. Liabilities, Contingencies and Assessments (Continued)

In April 2016, the DOL issued regulations expanding the definition of "investment advice" and broadening the circumstances under which distributors and manufacturers of insurance and annuity products could be considered "fiduciaries" and subject to certain standards in providing advice. These regulations were vacated effective June 2018. Thereafter, the DOL issued proposed regulatory action to address the vacated definition and issued final regulatory action on December 15, 2020. The DOL's final guidance confirms the reinstatement of the definition of "investment advice" that applied prior to 2016 but broadens the circumstances under which producers, including insurance producers, could be considered fiduciaries under ERISA in connection with recommendations to "rollover" assets from a qualified retirement plan to an IRA. This guidance reverses an earlier DOL interpretation suggesting that rollover advice did not constitute investment advice giving rise to a fiduciary relationship. In connection with the final regulatory action, the DOL issued a prohibited transaction class exemption that would allow fiduciaries to receive compensation in connection with providing investment advice, including advice about rollovers, that would otherwise be prohibited as a result of their fiduciary relationship to the ERISA Plan. We are reviewing the final guidance to determine how it might apply to and impact our business.

In addition to the cases previously discussed, the Company is routinely involved in litigation and other proceedings, reinsurance claims and regulatory proceedings arising in the ordinary course of its business. At present, no contingencies related to pending litigation and regulatory matters are considered material in relation to the financial position of the Company.

- 15. Leases None
- 16. Information About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk No Significant Changes
- 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities None
- 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans None
- 19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators None
- 20. Fair Value Measurements
 - A. Fair Value Measurement
 - (1) Fair value measurements at reporting date

a. Assets at fair value Bonds: Corporate \$ \$ \$ 5.459,420 447,510 5,906,930 Bonds: CMBS. 5,459,420 447,510 5,906,930 Bonds: RMBS 5,459,420 12,235,000 113,832,684 Common stocks: affiliated 33,511,288 90,048,691 14,272,705 137,832,684 Common stocks: affiliated 2,780		Description for each class of asset or liability	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Total
Bonds: CMBS. 5,459,420 447,510 5,906,930 Bonds: RMBS. 25,369,871 25,369,871 Preferred stocks: unaffiliated 112,235,000 112,235,000 Preferred stocks: affiliated 61,595,235 61,595,235 Common stocks: unaffiliated 33,511,288 90,048,691 14,272,705 137,832,684 Common stocks: affiliated 2,780 2,780 2,780 Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ \$ \$27,450,620 b. Liabilities at fair value \$ \$ 15,561,147 \$ \$ \$ \$ \$27,450,620 b. Liabilities: Options \$ \$ \$ 15,561,147 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	a.	Assets at fair value					
Bonds: RMBS 25,369,871 25,369,871 Preferred stocks: unaffiliated 112,235,000 112,235,000 Preferred stocks: affiliated 61,595,235 61,595,235 Common stocks: unaffiliated 33,511,288 90,048,691 14,272,705 137,832,684 Common stocks: affiliated 2,780 2,780 2,780 Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620 b. Liabilities at fair value \$ 15,561,147 \$ \$ 527,450,620 b. Liabilities: Interest rate swaps 144,477 1,235,052 13,379,529 Derivative liabilities: Interest rate swaps 144,477 1,235,052 13,379,529 Derivative liabilities: Variable products 32,044,323 32,044,323		Bonds: Corporate	\$ 	\$ 	\$ 578,865	\$	\$ 578,865
Preferred stocks: unaffiliated 112,235,000 112,235,000 Preferred stocks: affiliated 61,595,235 61,595,235 Common stocks: unaffiliated 33,511,288 90,048,691 14,272,705 137,832,684 Common stocks: affiliated 2,780 2,780 2,780 Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Futures 26,456,322 26,456,322 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ \$27,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ \$ 15,561,147 \$ \$ \$2,450,620 b. Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 3,317,967		Bonds: CMBS.	 	 5,459,420	447,510		 5,906,930
Preferred stocks: affiliated 61,595,235 61,595,235 Common stocks: unaffiliated 33,511,288 90,048,691 14,272,705 137,832,684 Common stocks: affiliated 2,780 2,780 Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Futures 26,456,322 26,456,322 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ \$ 15,561,147 \$ \$ 15,561,147 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Bonds: RMBS	 	 25,369,871			 25,369,871
Common stocks: unaffiliated 33,511,288 90,048,691 14,272,705 137,832,684 Common stocks: affiliated 2,780 2,780 Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Futures 26,456,322 26,456,322 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ \$ 15,561,147 \$ \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Preferred stocks: unaffiliated	 	 112,235,000			 112,235,000
Common stocks: affiliated 2,780 2,780 Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Futures 26,456,322 26,456,322 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ \$ 15,561,147 \$ \$ \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Preferred stocks: affiliated	 	 	61,595,235		 61,595,235
Derivative assets: Options 84,201,139 84,201,139 Derivative assets: Currency swaps 1,223,452 1,223,452 Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Futures 26,456,322 26,456,322 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ \$ 15,561,147 \$ \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Common stocks: unaffiliated	 33,511,288	 90,048,691	14,272,705		 137,832,684
Derivative assets: Currency swaps		Common stocks: affiliated	 	 	2,780		 2,780
Derivative assets: Total Return Swaps 3,560,730 3,560,730 Derivative assets: Futures 26,456,322 26,456,322 Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ 15,561,147 \$ \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Derivative assets: Options	 	 84,201,139			 84,201,139
Derivative assets: Futures 26,456,322		Derivative assets: Currency swaps	 	 1,223,452			 1,223,452
Derivative assets: Forwards 36,442,711 36,442,711 Separate account assets: Variable products 32,044,902 32,044,902 32,044,902 59,967,610 \$390,585,916 \$76,897,094 \$527,450,620 \$527,450,620 \$57,450,620		Derivative assets: Total Return Swaps	 	 3,560,730			 3,560,730
Separate account assets: Variable products 32,044,902 32,044,902 Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ 527,450,620 b. Liabilities at fair value Derivative liabilities: Options \$ 15,561,147 \$ \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Derivative assets: Futures	 26,456,322	 			 26,456,322
Total assets at fair value/NAV \$ 59,967,610 \$ 390,585,916 \$ 76,897,094 \$ \$ 527,450,620		Derivative assets: Forwards	 	 36,442,711			 36,442,711
b. Liabilities at fair value Derivative liabilities: Options. \$ 15,561,147 \$ \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 Derivative liabilities: Forwards 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Separate account assets: Variable products	 	 32,044,902			 32,044,902
Derivative liabilities: Options \$ 15,561,147 \$ 15,561,147 Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Total assets at fair value/NAV	\$ 59,967,610	\$ 390,585,916	\$ 76,897,094	\$	\$ 527,450,620
Derivative liabilities: Interest rate swaps 144,477 1,235,052 1,379,529 Derivative liabilities: Forwards 3,317,967 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323	b.	Liabilities at fair value					
Derivative liabilities: Forwards 3,317,967 Separate account liabilities: Variable products 32,044,323 32,044,323		Derivative liabilities: Options	\$ 	\$ 15,561,147	\$	\$	\$ 15,561,147
Separate account liabilities: Variable products 32,044,323 32,044,323		Derivative liabilities: Interest rate swaps	 144,477	 1,235,052			 1,379,529
		Derivative liabilities: Forwards	 	 3,317,967			 3,317,967
Total liabilities at fair value		Separate account liabilities: Variable products	 	 32,044,323			 32,044,323
		Total liabilities at fair value	\$ 144,477	\$ 52,158,489	\$	\$	\$ 52,302,966

(2) Fair value measurements in Level 3 of the fair value hierarchy

	Description	Ending balance as of 12/31/2020	Transfers Into Level 3	Transfers Out of Level 3	Total Gains and (Losses) Included in Net Income	Total Gains and (Losses) Included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance for 03/31/2021
a.	Assets										
	Bonds: Corporate	\$	\$ 392,342	\$	\$(22,851)	\$ 209,374	\$	\$. \$	\$	\$ 578,865
	Bonds: CMBS	1,277,247		(745,920)	11,201	(95,018)					447,510
	Preferred stocks: affiliated	7,717,662	31,855,516			4,501,908	18,135,000		(614,851).		61,595,235
	Common stocks: unaffiliated	10,499,824			105,610	3,667,271					14,272,705
	Common stocks: affiliated	2,780									2,780
	Total assets	\$ 19,497,513	\$ 32,247,858	\$ (745,920)	\$ 93,960	\$ 8,283,535	\$ 18,135,000	\$	\$ (614,851)	\$	\$ 76,897,094
b.	Liabilities										
	Total liabilities	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$

Transfers between fair value hierarchy levels are recognized at the end to the period in which the transfer occurs. Transfers into and out of Level 3 represent securities which are carried at lower of cost or fair value resulting in periodic transfers into and out of Level 3 financial instruments which are characterized as carried at fair value. Preferred stock transfers into Level 3 are due to the adoption of revised guidance in SSAP No. 32R, which requires perpetual preferred stock to be carried at fair value.

(3) Transfers between fair value hierarchy levels are recognized at the end of the period in which the transfer occurs.

20. Fair Value Measurements (Continued)

(4) The following discussion describes the valuation methodologies and inputs used for assets and liabilities measured and disclosed at fair ralue. The techniques utilized in estimating the fair values of financial instruments are reliant on the assumptions used

Fair value estimates are based on quoted market prices when available. When quoted market prices are not available, the Company utilizes commercially available pricing vendors that utilize observable market inputs, like recent trading activity, to derive fair value. When vendor prices are not available, fair value is generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality (matrix pricing). In instances where there is little or no market activity for the same or similar instruments, the Company estimates the fair value using methods, models and assumptions that management believes market participants would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment which becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect risk inherent in a particular methodology, model or input employed.

The Company's financial assets and liabilities carried at estimated fair value have been classified, for disclosure purposes, based on a hierarchy defined by current accounting guidance. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The levels of the fair value hierarchy are as follows:

- Level 1 Unadjusted quoted prices for identical assets or liabilities in an active market.
- Level 2 Quoted prices for inactive markets or valuation techniques that require observable direct or indirect inputs for substantially the full term of the asset or liability.

Level 2 inputs include the following:

- Quoted prices for similar assets or liabilities in active markets,
 Observable inputs other than quoted market prices, and
- 3. Observable inputs derived principally from market data through correlation or other means.
- Level 3 Prices or valuation techniques with unobservable inputs significant to the overall fair value estimate. These valuations use
 critical assumptions not readily available to market participants. Level 3 valuations are based on market standard valuation
 methodologies, including discounted cash flows, matrix pricing, or other similar techniques.

Assets and liabilities are valued as discussed below in part C.

- (5) See parts (1) through (4) above.
- Other Fair Value Disclosures None
- C. Fair Values for All Financial Instruments by Level 1, 2 and 3

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Assets - Bonds	\$ 44,717,842,961	\$ 42,287,499,097	\$ 4,369,474	\$ 40,670,891,400	\$ 4,042,582,087	\$	\$
Assets - Preferred stocks	328,258,137	316,524,252		196,447,637	131,810,500		
Assets - Common stocks unaffiliated	137,835,464	137,835,464	33,511,288	90,048,691	14,275,485		
Assets - Mortgage loans - first liens	8,746,585,518	8,482,028,922			8,746,585,518		
Assets - Mortgage loans - other than							
first liens							
Assets - Policy loans	142,025,148	142,025,148		142,025,148			
Assets - Cash and short-term investments	3,065,204,355	3,065,192,930	3,015,230,668	47,116,544	2,857,143		
Assets - Derivative assets	2,790,530,744	849,848,419	34,024,402	2,756,506,342			
Assets - Derivative collateral assets	52,763,118	52,763,118	52,763,118				
Assets - Other invested assets	3,877,402,063	3,785,480,905		511,360,894	1,543,516,113	1,822,525,055	
Assets - Separate account: variable products	32,044,902	32,044,902		32,044,902			
Assets - Separate account: group annuity	18,049,006,829	17,631,397,433	1,669,556,762	14,202,600,681	2,000,532,814	176,316,572	
Assets - Separate account: index- linked products	358 521 858	363 865 202	56 016 138	296 285 719	6 220 000		
Liabilities - Deposit-type contracts			, ,				
Liabilities - Repurchase agreements							
Liabilities - Derivative liabilities							
Liabilities - Derivative and other	100,000,200	101,001,110			1,017,112		
collateral	2,619,700,750	2,619,700,750	2,619,700,750				
Liabilities - Separate account: group annuity deposit-type contracts	2,752,882	2,874,733			2,752,882		
Liabilities - Separate account: funding agreements	2,052,651,191	1,919,322,986		2,052,651,191			

Bonds and short-term investments – The Company obtains the fair value for most marketable, public bonds without an active market from several commercial pricing services. These are classified as Level 2 assets. The pricing services incorporate a variety of market observable information in their valuation techniques, including benchmark yields, broker-dealer quotes, credit quality, issuer spreads, bids, offers, and other reference data. If the Company cannot value a public bond with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3. The Company values privately placed bonds based on the credit quality and duration of comparable marketable securities, which may be securities of another issuer. In some instances, the Company uses a matrix-based pricing model. These models consider the current level of risk-free interest rates, corporate spreads, credit quality of the issuer, and cash flow characteristics of the security. Privately placed fixed maturity securities are classified as Level 2 or 3.

20. Fair Value Measurements (Continued)

Preferred stocks and common stocks unaffiliated – The Company values equity securities, typically private equities or equity securities not traded on an exchange, using several commercial pricing services or an internal model. The securities priced by a commercial pricing service are classified as Level 2 and the securities priced by an internal model are classified as Level 3. In addition, unaffiliated common stocks include FHLB stock, which is carried at fair value, which is presumed to be par because it can only be redeemed by the bank and is classified as Level 2

Mortgage loans – The Company estimates mortgage loans on a monthly basis using discounted cash flow analysis and rates being offered for similar loans to borrowers with similar credit ratings. Loans with similar characteristics are aggregated for purposes of the calculations. The discounted cash flow model uses unobservable inputs, including estimates of discount rates and loan prepayments. Mortgage loans are classified as Level 3.

Policy loans – The fair value of policy loans classified as Level 2 is equal to the carrying value of the loans, which are collateralized by the cash surrender value of the associated insurance contracts.

Derivatives – Derivative contracts can be exchange traded or over-the-counter. Over-the-counter derivatives are valued using valuation models or an income approach using third-party broker valuations. Valuation models require a variety of inputs, including contractual terms, market prices, yield curves, measures of volatility, prepayment rates, and correlation of the inputs. The Company considers and incorporates counterparty credit risk in the valuation process through counterparty credit rating requirements and monitoring of overall exposure. The Company also evaluates and includes its own nonperformance risk in valuing derivatives. The majority of the Company's derivatives trade are in liquid markets; therefore, the Company can verify model inputs and model selection does not involve significant management judgment and are classified within Level 2. If the Company cannot verify model inputs and model selection does involve significant management judgment, the derivatives are classified as Level 3.

Other invested assets – Within other invested assets, partnerships are valued based on net asset value information provided by the general partner or related asset manager. These partnership interests usually include multiple underlying investments for which either observable market prices or other valuation methods are used to determine the fair value. These investments are reported in the Net Asset Value (NAV) column. Other than partnerships, other invested assets may include surplus notes and other investments with bond or stock characteristics and the Company attempts to value these using several commercial pricing services, which would be classified as Level 2 assets. If the Company cannot value with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3 assets.

Separate account assets (variable products) – Separate account assets classified as Level 2 are valued based on the fair value of the underlying funds. Fair values and changes in the fair values of the underlying funds accrue directly to the policy owners and are not included in the Company's revenues and expenses or surplus.

Separate account assets (group annuity) – Financial instruments within this separate account classified as Level 2 and 3 or included in the NAV column are valued using the same fair value assumptions and methods utilized in the general account.

Repurchase agreements - The carrying value of the repurchase agreements liability approximates fair value and is reported as level 2.

Deposit-type contracts (including separate account group annuity and funding agreements) – Deposit-type contracts classified as Level 3 include single premium immediate annuities (SPIA) and supplemental contracts. Fair value of SPIA and supplemental contracts are calculated by discounting best estimate cash flows based on mortality and market interest rate assumptions. Fair value of funding agreements are calculated by discounting future cash flows using market rates on the valuation date, and are classified as Level 2.

- D. Not Practicable to Estimate Fair Value None
- E. Nature and Risk of Investments Reported at NAV

The Company invests in certain non-fixed income, alternative investments in the form of limited partnerships (investment funds) which are reported at NAV. Adjustments to the carrying amount reflect the Company's pro rata ownership percentage of the operating results as indicated by NAV in the investment fund financial statements. The NAV from the investment fund financial statements can be on a lag of up to three months when investee information is not received in a timely manner. These investments are listed in the NAV column of the fair value tables above as this is the primary method for reporting fair value for these investments.

As of March 31, 2021, the Company's general and separate accounts have \$1,052.5 million unfunded commitments to invest in these investment funds.

21. Other Items - No Significant Changes

22. Events Subsequent

Subsequent events have been considered through May 13, 2021 for the statutory statement dated March 31, 2021.

During April 2021, the Texas Group Annuity Commingled Separate Account repaid \$100 million of seed money plus \$7.6 million of interest to the Company's general account.

During April 2021, the Company borrowed \$470 million with an interest rate of 0.3% under the FHLB short-term arrangement. The borrowing was repaid during April 2021.

Effective May 1, 2021, the Company entered into an unsecured revolving promissory note (the Promissory Note), with Athene USA (AUSA) and certain of AUSA's other subsidiaries, pursuant to which the Company and other borrower parties thereto may borrow up to \$200 million from AUSA. The Promissory Note was approved by the lowa Insurance Division. Interest shall accrue on the principal balance from time to time outstanding at a rate per annum equal to 2.085%. The Company shall pay such interest in arrears quarterly on the last day of each March, June, September and December, on any day any portion of the principal balance is repaid or prepaid.

The Company did not write any accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act.

23. Reinsurance - No Significant Changes

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

- A. Method Used to Estimate None
- B. Method Used to Record None
- C. Amount and Percent of Net Retrospective Premiums None
- D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act None

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination (Continued)

- E. Risk-Sharing Provisions of the Affordable Care Act (ACA)
 - (1) Accident and health insurance premium subject to the Affordable Care Act risk-sharing provisions

Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions? NO

- (2) Impact of Risk-Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year None
- (3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance None
- (4) Roll-forward of risk corridors asset and liability balances by program benefit year None
- (5) ACA risk corridors receivable as of reporting date None
- 25. Change in Incurred Losses and Loss Adjustment Expenses None
- 26. Intercompany Pooling Arrangements None
- 27. Structured Settlements None
- 28. Health Care Receivables None
- 29. Participating Policies No Significant Changes
- 30. Premium Deficiency Reserves None
- 31. Reserves for Life Contracts and Annuity Contracts No Significant Changes
- 32. Analysis of Annuity Actuarial Reserves and Deposit Type Contract Liabilities by Withdrawal Characteristics No Significant Changes
- 33. Analysis of Life Actuarial Reserves by Withdrawal Characteristics No Significant Changes
- 34. Premiums and Annuity Considerations Deferred and Uncollected No Significant Changes
- 35. Separate Accounts

In accordance with a 2019 consent order entered into with the NYDFS, during 2020, the Company began the process of transferring to AANY, its subsidiary, primary responsibility for New York residents entitled to payments under certain existing PRT transactions. On October 22, 2020, the Company entered into an Assignment Agreement with AANY pursuant to which the Company assigned all rights and obligations related to certain individuals entitled to annuity payments from existing PRT business and transferred net invested assets with a carrying value of \$32.0 million in 2020 and \$102.6 million in 2021. In connection with the transfer of its primary obligations to AANY, the Company released statutory reserves of \$25.8 million in 2020 and \$88.3 million in 2021. After considering the affects of reinsurance, the Company's separate accounts recognized an aggregate net loss of \$1.2 million in 2020 and \$2.9 million in 2021. In the remote scenario and only to the extent AANY is unable to perform its obligations to New York residents entitled to payments under the existing assigned PRT transactions, the Company will be required to satisfy any of the remaining obligations.

- A. Separate Account Activity No Significant Changes
- B. General Nature and Characteristics of Separate Accounts Business No Significant Changes
- C. Reconciliation of Net Transfers To or (From) Separate Accounts No Significant Changes
- 36. Loss/Claim Adjustment Expenses None